Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enterovirus type 71 inactivated vaccine is a **prophylactic inactivated viral vaccine** intended to prevent hand, foot and mouth disease caused by enterovirus A71 infection. It induces EV71-specific neutralizing immune responses after intramuscular administration and does not protect against HFMD caused by other enteroviruses such as coxsackievirus A16. The Mellow Hope product listing specifically describes a human-diploid-cell EV71 inactivated vaccine supplied as a liquid injection; this presentation is consistent with the human-diploid-cell product marketed as EntroVac by the Institute of Medical Biology, Chinese Academy of Medical Sciences. ([english.mellowhope.com](https://english.mellowhope.com/product-en/96.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on enterovirus type 71 inactivated vaccine.